Comments on: Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide

Comments on: Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide https://www.worldpharmatoday.com/clinical-trails/amgen-and-ucb-announce-positive-top-line-results-from-open-label-phase-3-study-of-romosozumab-compared-with-teriparatide/ Magazine for the C-level Pharma Executives Sun, 27 Sep 2015 23:39:14 +0000 hourly 1 https://wordpress.org/?v=6.9.4